An Investigative Analysis of Pharmaceutical and Biotech Valuation Frameworks Why Most Biotech Valuations Get It Wrong Every quarter, analysts revise […]

What You Actually Need to Know About the Dual Shield Most people conflate drug patents with drug exclusivity. They are

How generic drug companies legally exploit the Hatch-Waxman framework to generate billion-dollar windfalls — and how brand manufacturers fight back

The Patent Clock Nobody Shows You The standard answer to “how long does a patent last?” is 20 years. You

How payers, PBMs, and formulary committees can convert LOE intelligence into measurable cost savings — and why most of them

A Practical Guide to Tracking Competitors’ R&D Pipelines Before They Make Headlines The Intelligence Gap That Costs Billions Every pharmaceutical

The Decision That Defines Decades of Revenue Somewhere between the FDA approval notice hitting a pharmaceutical company’s inbox and the

Patent Terms, Data Exclusivity, Compulsory Licensing, and Generic Entry Across 11 Markets Why South America Is the World’s Most Contested

A $28 Billion Opportunity Most Vendors Are Missing The 505(b)(2) pathway generates billions in annual drug revenue and runs on